Cempra, Inc. (NASDAQ:CEMP)‘s stock had its “hold” rating restated by analysts at Jefferies Group LLC in a research report issued on Thursday. They currently have a $3.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s price target would indicate a potential downside of 4.00% from the company’s current price.

Several other research analysts have also commented on CEMP. ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price objective on shares of Cempra in a report on Thursday, August 10th. Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. Finally, Zacks Investment Research raised Cempra from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a research note on Friday, August 11th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Cempra (CEMP) traded up 0.81% during trading on Thursday, hitting $3.12. 769,968 shares of the company traded hands. The company’s market capitalization is $164.08 million. The stock has a 50 day moving average price of $3.33 and a 200 day moving average price of $3.82. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95.

Cempra (NASDAQ:CEMP) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $3.58 million. During the same quarter in the previous year, the firm earned ($0.51) EPS. The company’s quarterly revenue was down 74.9% compared to the same quarter last year. On average, equities analysts anticipate that Cempra will post ($1.01) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Cempra, Inc. (CEMP) Given Hold Rating at Jefferies Group LLC” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/cempra-inc-cemp-given-hold-rating-at-jefferies-group-llc.html.

A number of hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in Cempra by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 39,499 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 1,870 shares during the period. Teachers Advisors LLC grew its stake in Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock worth $262,000 after purchasing an additional 4,632 shares during the period. Voya Investment Management LLC grew its stake in Cempra by 34.1% in the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 5,848 shares during the period. Janney Montgomery Scott LLC grew its stake in Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 6,800 shares during the period. Finally, Northern Trust Corp grew its stake in Cempra by 1.3% in the second quarter. Northern Trust Corp now owns 546,294 shares of the biotechnology company’s stock worth $2,513,000 after purchasing an additional 6,846 shares during the period. 49.76% of the stock is currently owned by institutional investors.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.